The neurobiology of schizophrenia: new leads and avenues for treatment

Nicholas J. Bray; F. Markus Leweke; Shitij Kapur; Andreas Meyer-Lindenberg

doi:10.1016/j.conb.2010.09.008

The neurobiology of schizophrenia: new leads and avenues for treatment

Nicholas J. Bray, F. Markus Leweke, Shitij Kapur, Andreas Meyer-Lindenberg

Heidelberg University

Research output: Contribution to journal › Article › peer-review

18 Citations (Scopus)

Abstract

Recent large-scale genetic studies have provided robust evidence implicating several novel susceptibility genes for schizophrenia. These include ZNF804A, TCF4 and NRGN, which contain common variants that weakly increase schizophrenia susceptibility, and NRXN1, in which rare copy number variants have a greater impact on schizophrenia risk. Investigation of these and other substantiated susceptibility genes are providing valuable insight into the primary neurobiological mechanisms underlying schizophrenia, which may lead to novel therapeutic interventions for the disorder. In the meantime, several novel pharmacological strategies, including activation of mGluRs, elevation of synaptic glycine and inhibition of phosphodiesterase 10A, have recently shown promise for the treatment of schizophrenia in clinical trials.

Original language	English
Pages (from-to)	810 - 815
Number of pages	6
Journal	CURRENT OPINION IN NEUROBIOLOGY
Volume	20
Issue number	6
DOIs	https://doi.org/10.1016/j.conb.2010.09.008
Publication status	Published - Dec 2010

Access to Document

10.1016/j.conb.2010.09.008

Cite this

@article{d361a97340144b0faa44e7d62fb2f30e,

title = "The neurobiology of schizophrenia: new leads and avenues for treatment",

abstract = "Recent large-scale genetic studies have provided robust evidence implicating several novel susceptibility genes for schizophrenia. These include ZNF804A, TCF4 and NRGN, which contain common variants that weakly increase schizophrenia susceptibility, and NRXN1, in which rare copy number variants have a greater impact on schizophrenia risk. Investigation of these and other substantiated susceptibility genes are providing valuable insight into the primary neurobiological mechanisms underlying schizophrenia, which may lead to novel therapeutic interventions for the disorder. In the meantime, several novel pharmacological strategies, including activation of mGluRs, elevation of synaptic glycine and inhibition of phosphodiesterase 10A, have recently shown promise for the treatment of schizophrenia in clinical trials.",

author = "Bray, {Nicholas J.} and Leweke, {F. Markus} and Shitij Kapur and Andreas Meyer-Lindenberg",

year = "2010",

month = dec,

doi = "10.1016/j.conb.2010.09.008",

language = "English",

volume = "20",

pages = "810 -- 815",

journal = "CURRENT OPINION IN NEUROBIOLOGY",

issn = "1873-6882",

publisher = "Elsevier Limited",

number = "6",

}

TY - JOUR

T1 - The neurobiology of schizophrenia: new leads and avenues for treatment

AU - Bray, Nicholas J.

AU - Leweke, F. Markus

AU - Kapur, Shitij

AU - Meyer-Lindenberg, Andreas

PY - 2010/12

Y1 - 2010/12

N2 - Recent large-scale genetic studies have provided robust evidence implicating several novel susceptibility genes for schizophrenia. These include ZNF804A, TCF4 and NRGN, which contain common variants that weakly increase schizophrenia susceptibility, and NRXN1, in which rare copy number variants have a greater impact on schizophrenia risk. Investigation of these and other substantiated susceptibility genes are providing valuable insight into the primary neurobiological mechanisms underlying schizophrenia, which may lead to novel therapeutic interventions for the disorder. In the meantime, several novel pharmacological strategies, including activation of mGluRs, elevation of synaptic glycine and inhibition of phosphodiesterase 10A, have recently shown promise for the treatment of schizophrenia in clinical trials.

AB - Recent large-scale genetic studies have provided robust evidence implicating several novel susceptibility genes for schizophrenia. These include ZNF804A, TCF4 and NRGN, which contain common variants that weakly increase schizophrenia susceptibility, and NRXN1, in which rare copy number variants have a greater impact on schizophrenia risk. Investigation of these and other substantiated susceptibility genes are providing valuable insight into the primary neurobiological mechanisms underlying schizophrenia, which may lead to novel therapeutic interventions for the disorder. In the meantime, several novel pharmacological strategies, including activation of mGluRs, elevation of synaptic glycine and inhibition of phosphodiesterase 10A, have recently shown promise for the treatment of schizophrenia in clinical trials.

U2 - 10.1016/j.conb.2010.09.008

DO - 10.1016/j.conb.2010.09.008

M3 - Article

SN - 1873-6882

VL - 20

SP - 810

EP - 815

JO - CURRENT OPINION IN NEUROBIOLOGY

JF - CURRENT OPINION IN NEUROBIOLOGY

IS - 6

ER -

The neurobiology of schizophrenia: new leads and avenues for treatment

Abstract

Access to Document

Fingerprint

Cite this